<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mods:titleInfo><mods:title>PEG-INF ALFA-2B (ALGERON)  VA TENOFOVIR ALAFENAMID (TAF) KOMBINATSIYASINING SURUNKALI DELTA GEPATITNI DAVOLASHDAGI SAMARADORLIGINI BAHOLASH</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Raimov Kamol</mods:namePart><mods:namePart type="family">Eshmo’minovich</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Surunkali delta gepatit (SDG) – gepatit B virusi (HBV) bilan birgalikda yuquvchi kasallik bo‘lib, jigar to‘qimasida og‘ir yallig‘lanish va fibroz jarayonlarini keltirib chiqaradigan kasallikdir. SDG dunyo bo‘yicha gepatitlar orasida eng xavfli va davolashda murakkab bo‘lgan turlaridan biri hisoblanadi.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2025-11-20</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>"Research Science and Innovation house" LLC</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>